In this edition:
FORTIFY OLE: risankizumab in Crohn’s disease
In utero exposure to tofacitinib, upadacitinib or filgotinib in IBD
Diet & relapse in Crohn’s disease & UC
TURN 2: anaerobically-processed, donor-selected, dual-route FMT vs. autologous FMT in UC
ATTIC: micro-fragmented autologous adipose tissue injection for Crohn’s complex perianal fistulas
Advanced therapies for refractory pouchitis in ileal-pouch-anal anastomosis
Tofacitinib vs. upadacitinib in acute severe UC
GETAID: ustekinumab in fistulising perianal Crohn’s disease
GLADIATOR: etrasimod in mildly to moderately active UC
F. prausnitzii in Crohn’s disease
Please login below to download this issue (PDF)